TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
Want to see RNAZ full AI Analyst Report?
Total Valuation
TransCode Therapeutics has a market cap or net worth of $7.81M. The enterprise value is -$17.81B.
Market Cap$7.81M
Enterprise Value-$17.81B
Share Statistics
TransCode Therapeutics has 916,968 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding916,968
Owned by Insiders―
Owned by Institutions1.28%
Financial Efficiency
TransCode Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is 0.84%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)0.84%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee0.00
Profits Per Employee-4.95M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of TransCode Therapeutics is ―. TransCode Therapeutics’s PEG ratio is -0.01.
PE Ratio―
PS Ratio0.00
PB Ratio0.03
Price to Fair Value0.03
Price to FCF-0.24
Price to Operating Cash Flow-0.40
PEG Ratio-0.01
Income Statement
In the last 12 months, TransCode Therapeutics had revenue of 0.00 and earned -34.66M in profits. Earnings per share was -52.59.
Revenue0.00
Gross Profit0.00
Operating Income-27.98M
Pretax Income-34.44M
Net Income-34.66M
EBITDA-34.31M
Earnings Per Share (EPS)-52.59
Cash Flow
In the last 12 months, operating cash flow was -19.52M and capital expenditures -6.66K, giving a free cash flow of -19.52M billion.
Operating Cash Flow-19.52M
Free Cash Flow-19.52M
Free Cash Flow per Share-21.29
Dividends & Yields
TransCode Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.86
52-Week Price Change-28.11%
50-Day Moving Average9.31
200-Day Moving Average9.94
Relative Strength Index (RSI)48.33
Average Volume (3m)282.59K
Important Dates
TransCode Therapeutics upcoming earnings date is Mar 28, 2025, After Close (Confirmed).
Last Earnings DateNov 11, 2024
Next Earnings DateMar 28, 2025
Ex-Dividend Date―
Financial Position
TransCode Therapeutics as a current ratio of <0.01, with Debt / Equity ratio of 0.00%
Current Ratio<0.01
Quick Ratio<0.01
Debt to Market Cap0.00
Net Debt to EBITDA519.13
Interest Coverage Ratio-4.23K
Taxes
In the past 12 months, TransCode Therapeutics has paid 226.07K in taxes.
Income Tax226.07K
Effective Tax Rate>-0.01
Enterprise Valuation
TransCode Therapeutics EV to EBITDA ratio is 518.99, with an EV/FCF ratio of 912.20.
EV to Sales0.00
EV to EBITDA518.99
EV to Free Cash Flow912.20
EV to Operating Cash Flow912.51
Balance Sheet
TransCode Therapeutics has $17.81B in cash and marketable securities with $0.00 in debt, giving a net cash position of $17.81B billion.
Cash & Marketable Securities$17.81B
Total Debt$0.00
Net Cash$17.81B
Net Cash Per Share$19.43K
Tangible Book Value Per Share-$218.06K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for TransCode Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast93.85%